Advertisement
Advertisement
GPCR
Structure Therapeutics Inc. - ADR
36.91
USDSponsored
+0.10
+0.27%
Sep 22, 15:59 UTC -4
Closed
Pre-Market
36.74
-0.17
-0.46%
GPCR Earnings Reports
Positive Surprise Ratio
GPCR beat 2 of 15 last estimates.
13%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.59
Implied change from Q2 26 (Revenue/ EPS)
--
/+20.41%
Implied change from Q3 25 (Revenue/ EPS)
--
/-46.85%
Structure Therapeutics Inc. - ADR earnings per share and revenue
On Aug 06, 2026, GPCR reported earnings of -0.49 USD per share (EPS) for Q2 26, missing the estimate of -0.40 USD, resulting in a -20.81% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +1.79% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 12 analysts forecast an EPS of -0.59 USD, with revenue projected to reach -- USD, implying an increase of 20.41% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Structure Therapeutics Inc. - ADR's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Structure Therapeutics Inc. - ADR reported EPS of -$0.49, missing estimates by -20.81%, and revenue of $0.00, 0% as expectations.
How did the market react to Structure Therapeutics Inc. - ADR's Q2 2026 earnings?
The stock price moved up 1.79%, changed from $49.64 before the earnings release to $50.53 the day after.
When is Structure Therapeutics Inc. - ADR expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Structure Therapeutics Inc. - ADR's next earnings report?
Based on 12
analysts, Structure Therapeutics Inc. - ADR is expected to report EPS of -$0.59 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.